慢性淋巴细胞白血病化疗的回顾及进展

Systemic review on progress of drug therapy for chronic lymphocytic leukemia

随着核苷类似物及单克隆抗体,如利妥昔单抗(美罗华)和阿仑单抗的广泛应用,慢性淋巴细胞白血病(CLL)患者的第1次反应率和无进展生存期大幅度提高。尽管如此,复发或具有染色体异常等高危因素的CLL患者对治疗反应仍欠佳。近年来,临床对几类新药物的疗效和耐受性进行了深入研究,但其毒副作用并不令人满意。本文回顾CLL化疗的历史及新进展。

With the clinical use ofpurine analogues and monoclonal antibodies such as rituximab and alemtuzumab, the initial response rates and progression-free survival in patients with chronic lymphocytic leukemia （CLL） have greatly improved. Despite these advances, patients with CLL invariably experience relapse and often acquire high-risk chromosomal abnormalities, which result in resistance to current therapies. Recent clinical studies have examined the tolerability and efficacy of several novel agents in relapsed CLL. While these agents have demonstrated exciting clinical activity against genetically high-risk CLL, they have also induced toxicities that have not been commonly observed with previous CLL therapies. This paper focuses on progress of drug therapy for CLL.